Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1860657
Sentiment: neutral
Topics: 8-K, filing, regulatory
Related Tickers: ALLR
TL;DR
ALLR filed an 8-K, likely routine updates. Watch for details.
AI Summary
On February 6, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Allarity Therapeutics, Inc. is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific details of material events, making the immediate risk assessment low.
Key Numbers
- 20250206 — Report Date (Earliest event reported)
- 20250207 — Filing Date (Date the report was filed with the SEC)
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- 0001860657 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification Code
- 001-41160 (company) — SEC File Number
FAQ
What specific "Other Events" are being reported by Allarity Therapeutics, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The excerpt indicates that financial statements and exhibits are part of the filing, but their specific content is not described.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive office is located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the telephone number for Allarity Therapeutics, Inc.?
The registrant's telephone number is (401) 426-4664.
What is the Standard Industrial Classification (SIC) code for Allarity Therapeutics, Inc.?
The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-02-07 08:06:16
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ALLR The Nasdaq Stock Mark
Filing Documents
- allr20250206_8k.htm (8-K) — 28KB
- ex_775498.htm (EX-99.1) — 14KB
- atlogosmall.jpg (GRAPHIC) — 6KB
- 0001437749-25-003074.txt ( ) — 192KB
- allr-20250206.xsd (EX-101.SCH) — 3KB
- allr-20250206_def.xml (EX-101.DEF) — 12KB
- allr-20250206_lab.xml (EX-101.LAB) — 16KB
- allr-20250206_pre.xml (EX-101.PRE) — 12KB
- allr20250206_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 6, 2025, Allarity Therapeutics, Inc. (the "Company") issued a press release announcing expansion of the phase 2 clinical trial to accelerate development of stenoparib in advanced ovarian cancer. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated February 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: February 7, 2025 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer